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Abstract
Male breast cancer is a rare disease. The limited number of clinical cases has led to the primary treatments for men being
derived from female breast cancer studies. Here the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J (also known as PyVT)
was used as a model system for measuring tumor burden and drug sensitivity of the antineoplastic drugs tamoxifen,
cisplatin, and paclitaxel on tumorigenesis at an early stage of mammary carcinoma development in a male mouse model.
Cisplatin treatment significantly reduced tumor volume, while paclitaxel and tamoxifen did not attenuate tumor growth.
Cisplatin treatment was shown to induce apoptosis, grossly observed by reduced tumor formation, through reduced Bcl-2
and survivin protein expression levels with an increase in caspase 3 expression compared to control tumors. Tamoxifen
treatment significantly altered the hormone receptor expression levels of the tumor, while additionally upregulating Bcl-2
and Cyclin D1. This suggests an importance in hormonal signaling in male breast cancer pathogenesis. The results of this
study provide valuable information toward the better understanding of male breast cancer and may help guide treatment
decisions.
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Introduction
Male breast cancer accounts for 1% of all breast cancer cases in
the United States, while it causes approximately 0.5% of all male
cancer deaths [1]. Knowledge of this malignancy and appropriate
therapies remain limited due to rarity of large cohorts of male
breast cancer patients. Treatment for male breast cancer is
therefore extrapolated from controlled clinical studies conducted
in women [2]. Male breast cancer most commonly presents as late
stage painless, firm masses in the subareolar location that become
fixed to the pectoralis major muscle and the skin [3]. Male breast
cancer is diagnosed in later stages than female breast cancer,
leading to a tendency of small neoplasms to spread to the axillary
lymph nodes. The 5-year survival rate for metastatic breast cancer
in male patients is less than 20%, while the median survival is only
about 15 months [4,5]. Prognosis of male breast cancer is similar
to stage matched females.
Male breast cancer differs from female breast cancer in many
aspects. Most notably male breast cancer is diagnosed at older
ages, presents at higher stage, has a bimodal age-frequency [4,6],
racial differences [6], distinct histological subtypes, immunophe-
notypic variations [4,6,7], low survival rates [4], and differential
genetic mutations, such as CYP17 polymorphism [8], androgen
receptor (AR) [9], and CHEK2 mutations [10]. Male breast
cancer has also been shown to have a higher frequency of
hormone receptor (HR), estrogen receptor (ER) and progesterone
receptor (PR), expression (80–90%) compared to females (75%)
[4,5]. It is unclear if there is a relationship between ER+ male
breast carcinomas and patient survival [4,11,12]. This may be due
to differences in ER function in males as compared to females
[13]. There is an up-regulation of ER expression in males due to
the naturally lower estrogen levels in the tissue microenvironment,
leading to an increase in estrogen targets [14]. An example of this
is Bcl-2, which is an inhibitor of apoptosis, and has also been found
to be overexpressed in male breast cancer [15].
The molecular subtypes of male breast cancers are based on the
expression of certain protein markers in the neoplastic tissue,
which are used to evaluate their association with the observed
pathological features and patient outcome. It is important to note
that the HR positivity of male breast carcinomas may not have the
same prognostic value as female breast cancer. It is unclear
whether the human epidermal growth factor receptor 2 (HER2)
plays a prognostic or predictive role in male breast cancer [16,17].
In a comparative study between male and female invasive breast
carcinomas, the most common phenotype was luminal A (HR+/
HER22), while HR2 and HER2+ were not identified in male
patients [18]. In another study luminal A tumors were 82.8%,
luminal B (HR2/HER2+) tumors found in 6.2%, and basal-like
(HR2/HER22) tumors were found in 9.6% of the male breast
cancer cohort [19]. Contrary to these, another series reported to
have no significant difference between tumor subtypes [20]. These
studies show that the distribution of molecular subtypes in male
breast cancer varies, but that it is also different compared to the
female breast cancer cohorts. This is indicative of a pathological
difference in carcinogenesis between males and females.
Certain populations have a higher risk of developing male
breast cancer. The major risks are either genetic factors or
hormone imbalance. Approximately 20% of males with breast
cancer have a family history of breast or ovarian cancer [21].
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Mutations in the BRCA1 or BRCA2 genes are the strongest known
genetic risk factors for male breast cancer. More specifically the
BRCA2 gene mutation has a 7% lifetime risk of male breast cancer
[22], which is a greater risk than females with a genetic
predisposition of this disease. A change in the ratio of estrogen
and testosterone is also an important factor contributing to male
breast cancer. Individuals with Klinefelter’s syndrome have low
testosterone levels, increasing the lifetime risk of developing male
breast cancer to approximately 5% [21].
The commonly used therapeutic approach involves mastectomy
with axillary lymph node evaluation and hormonal therapy, with
potentially additional adjuvant chemotherapy. Hormonal therapy,
primarily tamoxifen, is the mainstay of treatment for male breast
cancer and is considered to be the first line treatment for
metastatic male breast cancer, with an overall response rate of
49% [23]. In another study [24], it was reported that tamoxifen
increased the 5-year actuarial survival (61% verse 44%) and
disease free survival (55% verse 28%) rates of 39 male breast
cancer patients compared with the historical control group [25].
Men in general tolerate tamoxifen well, with the most common
side effects reported as decreased libido, weight gain, hot flashes,
mood alteration and depression. However, it is important to note
that there have been no randomized trials to evaluate the real
response rates or the toxicity of tamoxifen in men. The role of
other antineoplastic drugs commonly used for female breast
cancer treatment has yet to be determined in male patients.
Advancements in diagnosis and treatment of female breast
cancer have resulted in a steady decline in incidence and clinical
outcome, while male breast cancer has been on a steady rise in
incidence over the past several decades and a much slower
improvement on clinical outcome [26]. The treatment for male
breast cancer is extrapolated from female clinical trials, despite
distinct clinical and pathological differences, as well as a lack of
clinical improvement in patient outcome. There is a need for new
clinical management of male breast cancer. The major hormonal
differences between male and female patients regarding endocri-
nology and the breast carcinomas’ response, suggests a need to
explore alternate treatment options.
The transgenic mouse strain FVB/N-Tg(MMTV-PyVT)634-
Mul/J (referred to as PyVT) is a novel in vivo model of mammary
tumor formation and metastasis. The PyVT model has mammary
tissue-specific expression of the Polyoma Virus middle T antigen
driven by the mouse mammary tumor virus promoter [27]. PyVT
premalignant tumors are morphologically heterogeneous with
abnormal microvasculature, highly proliferative with atypical
nuclei, and remain confined within the basement membrane prior
to lung metastasis [28]. Studies show that even at early stages of
mammary development the mammary fat pads were clearly
abnormal with irregular growth of side branches, enlarged
terminal buds, and large tumorous masses. Male animals generally
develop mammary tumors by 15 weeks of age and reach
maximum tumor burden around 25 weeks of age.
This study focuses on utilizing the in situ generation of male
mammary tumors by the PyVT model to determine the efficacy of
antineoplastic drugs, cisplatin, paclitaxel, and tamoxifen in
attenuating tumor growth. The potential benefits of each
treatment option are revealed for a male mammary tumor model.
Materials and Methods
Ethics Statement
Husbandry of animals is conducted by the Comparative
Medical Group (CMG) at the College of Veterinary Medicine at
Kansas State University. The CMG animal facilities are fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care, International (AAALAC). The compli-
ance to aspects of animal welfare law is regularly monitored by the
veterinary staff. Animal care and use protocols were approved by
the Institutional Animal Care and Use Committee (IACUC) at
Kansas State University (Protocol Number: 2975), Manhattan
following NIH guidelines.
Mouse Model
PyVT mice were purchased from the Jackson Laboratory (Bar
Harbor, Maine). The mice were monitored every other day to
check for the appearance of tumors. The tumor size was measured
in two dimensions with calipers. Mice were observed for abnormal
behavior, appearance or weight loss. If the animals showed any
signs of pain, extreme tumor growth (greater than 1.5 cm) or loss
of body condition, they were humanely euthanized before the end
of the experimentation period. At different time points (10, 15, 20
weeks of age) the mice were sacrificed to examine mammary
epithelium and tumor formation. All treatments were conducted
on mice determined to be in an early tumor development stage,
which was 15 weeks of age. Average weight of this age group was
28–32 grams. Mice were randomly divided into four experimental
groups: (1) control animals given the vehicle solvent (DMSO); (2)
animals treated with 3.5 mg/kg cisplatin; (3) animals treated with
10 mg/kg paclitaxel; and (4) animals treated with 40 mg/kg
tamoxifen. All treatments were administered as an intraperitoneal
injection.
Antibodies
Primary antibodies to Survivin (sc-8807, goat polyclonal),
Caspase 3 (sc-56046, mouse monoclonal), Cyclin D1 (sc-8396,
mouse monoclonal), Bcl-2 (sc-492, rabbit polyclonal), ERa (sc-
8002, mouse monoclonal), ERb (sc-8974, rabbit polyclonal) and
PR (sc-166170, mouse monoclonal) from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA); anti-GAPDH (2118, rabbit monoclonal)
and anti-HER2 (4290, rabbit monoclonal) from Cell Signaling
(Boston, MA) were used for both western blot and immunohis-
tochemistry (IHC).
Immunohistochemistry
All tumors were fixed in a solution of 10% formaldehyde and
embedded into paraffin prior to sectioning them onto slides at a
5 mm thickness. Paraffin sections (5 mm) were dried at 60uC for 25
minutes. Deparaffinization was performed with 100% xylene and
100%, 90%, 75%, 50% ethanol. Antigen retrieval was performed
in 16 Citrate buffer solution and steam. Slides were then
incubated overnight at room temperature with a polyclonal
antibody (1:50 dilution). After washes in PBS, slides were
successively incubated with biotinylated secondary antibodies
(1:1000) for 15 minutes. Slides were washed and immunostains
were amplified by incubation with Avidin Biotin Complex (ABC)
for 10 minutes accordingly. Cells were visualized with 3,3-
diaminobenzidine (DAB) followed by a hematoxylin counterstain.
The sections were viewed and the images captured with a Nikon
80i microscope.
Western Blot Analysis
Mammary gland tumor tissue were homogenized in 500 mL of
lysis buffer (20 mM Tris pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA,
0.5% Triton X-100) at 1:1000 dilution of protease inhibitors
(Sigma-Aldrich, Saint Louis, MO). Tissue was homogenized using
the OMNI Bead Ruptor 24 at a speed of 5.65 m/s for 45 seconds,
followed by centrifugation at 13,000 rpm for 30 minutes at 4uC.
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Twenty-five micrograms of whole-cell extract was resolved by 10%
SDS polyacrylamide gel electrophoresis (PAGE) and transferred to
nitrocellulose membrane (Midwest Scientific, Saint Louis, MO).
Nitrocellulose membranes were blocked with 0.5% milk in Tris-
Buffered Saline and Tween 20 (TBST) using a SNAP i.d. device
(Millipore) at room temperature. Membranes were then incubated
with primary antibody at a 1:1000 dilution, followed by HRP-
linked secondary antibodies (1:2000). Western blots were detected
by enhanced chemiluminescence detection reagents (Pierce,
Rockford, IL) and visualized by Fluorochem E imaging system
(ProteinSimple, Santa Clara, CA).
Statistical Analysis
Data is presented as the mean 6 the 95% confidence interval of
a minimum of three samples for molecular analysis and six samples
for animal studies. Significance was determined at a P-value
#0.05.
Results
Characterization of the PyVT Mouse Model and Effects of
Treatment on Hormone Receptor Expression
FVB/N-Tg(MMTV-PyVT)634Mul/J male transgenic mice
developed tumors as early as 14 weeks of age. All 10 mammary
pads developed tumors with the maximum tumor burden achieved
around 25 weeks of age. Tumor development in this spontaneous
model was divided into 3 stages based on the extent of tumor size,
the frequency of tumor formation, and whether it has metastasized
to the lungs. Pre stage of PyVT tumor development occurred from
10–13 weeks of age and consisted of a pre-cancerous condition
where no tumors were palpated and the mammary tissue appeared
normal on gross observation. The Early stage of development
represents solid tumor formation within the breast tissue at 15–18
weeks of age. This stage consisted of the gross observation of 1–2
solid tumors. The Late stage consisted of the presence of all 10
primary mammary tumors and secondary lung metastasis, which
occurred after 20 weeks of age. The presence of metastases was
confirmed by hematoxylin and eosin (H&E) staining of represen-
tative sections of the lung and histopathological review. This
report focused on the Early stage of tumor formation and
examined the effect of antineoplastic drugs on tumor growth at
this stage.
The mammary tumors were isolated from each treatment group
to determine hormone receptor (ER, PR, and HER2) expression.
Immunohistochemistry of the control tumor sections show weak
positive staining of HER2 and strong positive staining of ERb
(Fig. 1A). Tamoxifen treatment resulted in an increase in positive
nuclear staining of ERa in the tumors isolated, while decreasing
the positive staining of ERb. Western blot analysis was conducted
to determine quantifiable expression levels of each hormone
receptor in treated tissue. Controls tumors were shown to express
ERa, ERb, PR, and HER2 (Fig. 1B). Tamoxifen treated animals
had an increased expression of ERa (P-value = 0.0021) and PR (P-
value = 0.0300; Fig. 1B), while inducing a significant decrease in
HER2 (P-value = 0.0002) and ERb expression (P-value = 0.0002).
Mice receiving paclitaxel treatment had a significant reduction in
ERa and ERb expression compared to control mice (P-
value = 0.0201 and 0.0219, respectively), with no change in PR
and HER2 expression. Interestingly animals treated with cisplatin
showed no change in ERa, ERb, PR, or HER2 expression,
suggesting that treatment does not affect expression of the
molecular markers.
Effect of Cisplatin on Early Development of PyVT Mice
Tumor growth over a 14 day period with cisplatin treatment
every other day indicates a significant effect of treatment on
neoplastic development during the Early stage of tumor formation
(Fig. 2). The initial tumor volume for all mice was
66.86621.99 mm3. There was a significant difference in tumor
volumes between DMSO and cisplatin treated mice from day 8 to
day 14 (Fig. 2A). The final tumor volume for the control DMSO
treated mice was 293.33671.39 mm3, while the cisplatin treated
mice had a final volume of 100.186105.78 mm3. The change in
tumor volume over the 14 day period shows a significant reduction
of 215.59 mm3 with cisplatin treatment compared to control (P-
value = 0.00044; Fig. 2B). This is a 90.71% difference between the
overall changes in tumor growth after treatment with cisplatin.
Control mice have a total of 10 mammary fat pads that
developed tumors during the treatment period. Treatment with
cisplatin significantly reduced the number of tumors developed
compared to the control group (P-value ,0.0001; Fig. 2C). A total
of 4 tumors developed with cisplatin treatment during the 14 day
period.
Effect of Paclitaxel on Early Development of PyVT Mice
The initial tumor volume for all mice treated with either
paclitaxel or DMSO was 137.34693.05 mm3. There was not a
significant difference in tumor volumes between treatment groups
at any time during the 14 day treatment period (Fig. 3A). The
change in tumor growth over the 14 day treatment period
indicated that paclitaxel significantly attenuated tumor growth (P-
value = 0.029, Fig. 3B). The control mice had an overall tumor
growth of 237.68665.78 mm3, while those mice treated with
paclitaxel grew by 75.106134.57 mm3. Additionally, paclitaxel
treatment significantly reduced the tumor burden by an average of
2.5 tumors (P-value = 0.00022, Fig. 3C).
Effect of Tamoxifen on Early Development of PyVT Mice
The tamoxifen treated mice and respective control mice began
treatment with an initial tumor volume of was
127.916122.53 mm3. Tamoxifen treatment did not affect tumor
growth compared to the control animals during the treatment
period (Fig. 4A and 4B). There was, however, a significant
reduction in tumor burden by approximately 4 tumors (P-
value = 0.00478, Fig. 4C).
Protein Expression in Isolated PyVT Tumors
Immunoblot analysis was conducted to determine the expres-
sion of molecular markers for male breast cancer, including Bcl-2,
caspase-3, survivin, and cyclin D1 (Fig. 5A). Bcl-2 has been shown
to correlate with low mitotic cell count and lower grade tumors,
suggesting it can be an important biomarker in male breast cancer
pathogenesis [29]. Tamoxifen increased Bcl-2 by 65% compared
to control (P-value = 0.0131). Paclitaxel significantly reduced the
expression of Bcl-2 by 22% (P-value = 0.0346). There was an
insignificant decrease of 17% in Bcl-2 expression with cisplatin
treatment. Immunohistochemistry indicates strong positive stain-
ing of Bcl-2 in control and treated tumors (Fig. 5B). Tamoxifen
treated tumors appear to have a stronger staining of Bcl-2,
confirming western blot analysis.
The ability to induce apoptotic signaling in the tumor cells was
determined by analysis of caspase expression. Cisplatin increased
caspase 3 expression by 55% (P-value ,0.0001) compared to
control tumors (Fig. 5A). Tamoxifen and paclitaxel treatment did
not change the expression of caspase 3. Control tumors have very
weak positive staining for caspase 3. All antineoplastic compounds
Antineoplastic Drugs in a Male Mammary Tumor Model
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Figure 1. Male PyVT phenotype during early tumor development. A) Immunohistochemisty of tumor phenotype from PyVT males during
tumor development. Paraffin-embedded sections stained with antibodies against estrogen receptor (ERa and b), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER-2) at the early stage of development. Proteins staining: brown, counterstaining: blue (hematoxylin).
Images represent only 1 of 6 animals per group at a 60X magnification. B) Representative Western blot (n = 1) for hormone receptor expression in
tumors isolated from male PyVT. Graphical representation shows the percent of control protein expression determined by pixel intensity of ERa, PR,
HER2, and ERb in PyVT male tumors treated with DMSO (control), tamoxifen (40 mg/kg), paclitaxel (10 mg/kg) or cisplatin (3.5 mg/kg) via 7 IPs during
early tumor development. n = 4. *P-value ,0.05 compared to control.
doi:10.1371/journal.pone.0064866.g001
Antineoplastic Drugs in a Male Mammary Tumor Model
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e64866
show an increase in positive staining compared to control, but
cisplatin and tamoxifen have the strongest positive staining for
caspase 3 (Fig. 5B).
Tumor cells are highly proliferative; therefore we explored the
expression of cyclin D1 as a biomarker for cell proliferation. Cyclin
D1 is a key cell cycle regulator in which over expression results in
rapid progression from G1 to S phase in mitosis [30]. Analysis of
cyclin D1 expression indicated that tamoxifen significantly
increased expression by 96% (P-value = 0.0115), while paclitaxel
and cisplatin did not significantly alter expression levels (Fig. 5A).
Control tumors had weak positive staining for cyclin D1.
Tamoxifen treated tumors had a strong positive staining, while
paclitaxel and cisplatin treated tumors had weak positive staining
for cyclin D1 (Fig. 5B).
Proteins that inhibit apoptosis provide protection for tumor cells
against cytotoxic compounds. Survivin is a member of the
inhibitors of apoptosis protein family that is expressed during
Figure 2. Tumor growth (mm3) in PyVT male mice treated with
cisplatin. Tumors measured in two dimensions with calipers every 2
days prior to administration of treatment during early tumor
development. A) The tumor size is expressed over the 14 day treatment
period for the DMSO (control) and cisplatin (3.5 mg/kg) treated PyVT
mice. Days 0–12 represent the days of the 7 IP injections, day 14
represents the end of the study with measurements prior to tissue
harvest. B) The overall change in tumor size after treatment with DMSO
(control) or cisplatin (3.5 mg/kg) via 7 IP injections. C) Number of
developed tumors per PyVT male mouse during development. Tumors
identified grossly during the early stage of tumor development after a
14 day period with either treatment with DMSO (control) or cisplatin
(3.5 mg/kg) via 7 IP injections. *P-value ,0.05 compared to control.
doi:10.1371/journal.pone.0064866.g002
Figure 3. Tumor growth (mm3) in PyVT male mice treated with
paclitaxel. Tumors measured in two dimensions with calipers every 2
days prior to administration of treatment during early tumor
development. A) The tumor size is expressed over the 14 day treatment
period for the DMSO (control) and paclitaxel (10 mg/kg) treated PyVT
mice. Days 0–12 represent the days of the 7 IP injections, day 14
represents the end of the study with measurements prior to tissue
harvest. B) The overall change in tumor size after treatment with DMSO
(control) or paclitaxel (10 mg/kg) via 7 IP injections. C) Number of
developed tumors per PyVT male mouse during development. Tumors
identified grossly during the early stage of tumor development after a
14 day period with either treatment with DMSO (control) or paclitaxel
(10 mg/kg) via 7 IP injections. *P-value ,0.05 compared to control.
doi:10.1371/journal.pone.0064866.g003
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embryogenesis and in tumor cells as an anti-apoptotic protein that
is capable of regulating mitosis [31,32,33]. Survivin is highly
expressed in a range of tumors and its expression correlates with
both accelerated relapse and chemotherapy resistance [34].
Tamoxifen and cisplatin treatment significantly reduced survivin
expression by 77% (P-value = 0.0019) and 48% (P-value,0.0001),
respectively (Fig. 5A). Immunohistochemistry of the control
tumors showed strong positive staining for survivin (Fig. 5B).
Tumors treated with tamoxifen and cisplatin had weak positive
staining for survivin compared to paclitaxel and control tissue.
Pathological Review of Male Mammary Tumors
Pathological review of the mammary tumors was conducted for
each treatment group. The tumors were categorized as either early
carcinoma or late carcinoma. An early carcinoma consisted of a
moderately demarcated neoplasm with closely packed nests and
acini of proliferative neoplastic epithelial cells with cellular atypia
and invasion of the basement membrane. The late carcinoma
featured poorly demarcated neoplasms composed of sheets of
tightly packed nest/acini of neoplastic epithelial cells separated by
fibrovascular stroma with a loss of mammary architecture,
increased proliferation, and more extensive invasion.
Control tumors were characterized by focal hyperplasia with
normal lymph nodes and adipose tissue or early carcinoma lesions.
Treatment with cisplatin and paclitaxel had no significant change
in the histopathology, and tumors remained characteristic of early
carcinoma. Mice treated with tamoxifen developed tumors
characteristic of late carcinoma, suggesting an increase in
malignancy due to treatment.
Discussion
The transgenic PyVT model was used here for translational
studies of male breast cancer due to its clinically relevant
pathology and protein expression profile. Models for male breast
cancer are limited, but the lack of clinical patients make this
transgenic mouse model vital to gain an understanding about the
pathological differences in male breast cancer compared to the
female counterparts. The male PyVT model has provided an
opportunity to address the efficacy of treatment using the
antineoplastic drugs: tamoxifen, paclitaxel, and cisplatin. Tamox-
ifen is better known as a selective estrogen receptor modulator
(SERM) because of its multiple activities [35]. Due to the high
hormone receptor positivity in male breast cancer, tamoxifen is the
standard adjuvant therapy. Paclitaxel, approved by the Food and
Drug Administration (FDA) to treat ovarian and breast cancer, is a
first-line treatment of female metastatic breast cancer. Paclitaxel
promotes the stable assembly of microtubules and inhibits their de-
polymerization [36], therefore interfering with the normal
function of microtubules and preventing the progression of the
cell cycle [37]. Cisplatin is a platinum based chemotherapy drug
used to treat a variety of cancers through the formation of
platinum-DNA adducts that induce cell cycle arrest [38,39]. These
compounds have drastically different modes of action. Here we
determined the efficacy of each in attenuating mammary tumor
growth in a male model.
This study shows that early male mammary tumor formation is
significantly attenuated by cisplatin treatment, while tamoxifen
and paclitaxel have no effect on tumor growth. This suggests that
treatment options need to be reconsidered for male breast cancer
patients. Tamoxifen is the current primary treatment, but results
indicate that it does not efficiently attenuate tumor growth.
Cisplatin was shown to be the more efficient antineoplastic tested,
suggesting a switch in compounds for primary treatments of male
breast cancer patients. Interestingly all three antineoplastic
compounds, cisplatin, paclitaxel, and tamoxifen reduced the total
number of developed tumors, indicating they could have a
chemopreventive property.
Hormone receptor expression is the primary way to profile
mammary carcinomas. The male PyVT tumors were shown to be
ERa/b+, PR+, and HER2+. Tamoxifen treatment increased the
Figure 4. Tumor growth (mm3) in PyVT male mice treated with
tamoxifen. Tumors measured in two dimensions with calipers every 2
days prior to administration of treatment during early tumor
development. A) The tumor size is expressed over the 14 day treatment
period for the DMSO (control) and tamoxifen (40 mg/kg) treated PyVT
mice. Days 0–12 represent the days of the 7 IP injections, day 14
represents the end of the study with measurements prior to tissue
harvest. B) The overall change in tumor size after treatment with DMSO
(control) or tamoxifen (40 mg/kg) via 7 IP injections. C) Number of
developed tumors per PyVT male mouse during development. Tumors
identified grossly during the early stage of tumor development after a
14 day period with either treatment with DMSO (control) or tamoxifen
(40 mg/kg) via 7 IP injections. *P-value ,0.05 compared to control.
doi:10.1371/journal.pone.0064866.g004
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Figure 5. Expression of molecular markers Bcl-2, caspase 3, cyclin D1, and survivin. Tumors isolated from PyVT males treated with DMSO
(control), tamoxifen (20 mg/kg), paclitaxel (10 mg/kg), or cisplatin (3.5 mg/kg). A) Representative Western blot (n = 1) of protein expression in tumors
isolated from male PyVT. Graphical representation shows the percent of control protein expression determined by pixel intensity of Bcl-2, caspase 3,
cyclin D1, and survivin in PyVT male tumors during early tumor development. n = 4. *P-value,0.05 compared to control. B) Immunohistochemisty of
tumors from PyVT males. Paraffin-embedded sections stained with antibodies against Bcl-2, caspase 3, cyclin D1, or survivin from PyVT males.
Proteins staining: brown, counterstaining: blue (hematoxylin). Images represent only 1 of 3 samples per group at a 60X magnification.
doi:10.1371/journal.pone.0064866.g005
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expression of both ERa and PR, while resulting in a decreased
expression of HER2 and ERb, indicating an inverse relationship
between the ER isoforms due to tamoxifen treatment. Hormone
sensitive tumors are typically based on the expression of only ERa.
The role of ERb in the pathology and treatment of breast cancer
remains largely unknown. The functions of these two estrogen
receptors are drastically different in response to both estrogen and
anti-estrogenic compounds [40,41]. Multiple reports show that
estrogen exposure to ERa expressing breast cancer cells lead to an
increase in proliferation, while exposure to ERb expressing cells,
either alone or in combination with ERa, results in inhibition of
cellular proliferation [42,43,44]. This suggests that ERb may
function more as a tumor suppressor than a tumor promoter. The
expression of ERb has been found in 47% of breast tumors
classified as ERa negative [45]. Interestingly paclitaxel also
reduced the expression of ERb, but did not affect expression of
ERa, PR, or HER2. The clinical relevance of ERb expression is
uncertain, multiple studies indicate a correlation with improved
survival [46,47], while others suggest little correlation or worse
prognosis [48,49]. These findings emphasize the need to further
elucidate the function of ERb in the pathology and treatment of
breast cancer.
Tumor regression occurs when the rate of cellular proliferation
is less than the rate of cellular death. To determine the apoptotic
signaling due to the antineoplastic treatments, caspase 3 expression
levels were measures in all tumors. Cisplatin was the only
compound to induce a significant increase in caspase 3, indicating
induction of apoptosis due to treatment. This is observed grossly
by a significant reduction in tumor size. Tamoxifen and paclitaxel
did not have an observable apoptotic effect. The inhibitor of
apoptosis, survivin, was measured in tumor tissue after treatment
with the antineoplastic compounds. There was a significant
decrease in the expression of survivin after tamoxifen or cisplatin
treatment. This indicates that both treatments reduce the anti-
apoptotic signals, thus promoting cellular death. Cisplatin
treatment therefore promotes and induces apoptosis, resulting in
a decreased tumor volume. Tamoxifen treatment only promotes
apoptosis, thus sensitizing the cell for apoptotic signaling, but not
directly leading to cellular death.
Bcl-2 is another regulator of apoptosis, but has been shown to
be an important biomarker in male breast cancer pathogenesis,
correlating with low mitotic cell count and smaller tumors with
lower histological grade [29]. Bcl-2 is also a critical biomarker for
female breast cancer in predicting patient survival [50]. In this
study tamoxifen was shown to increase Bcl-2 expression, while
paclitaxel and cisplatin decreased expression levels compared to
control tumors. The expression of survivin with other anti-
apoptosis genes like Bcl-2 reduces apoptosis of cancer cells [51].
Bcl-2 expression is expected to correlate with survivin, which was
observed with cisplatin treatment in which both proteins have a
reduced expression compared to control tumors. Interestingly
tamoxifen treated tumors show an inverse relationship between
Bcl-2 and survivin. Bcl-2 proteins are found as dimers in the outer
mitochondrial membrane [52]. The physiological role of Bcl-2
expression and control of homeostasis in normal breast tissue is
suggested to involve upregulation by estradiol and down-regula-
tion by progesterone [53]. Additionally in breast cancer cells
estradiol was shown to stimulate, while progesterone inhibited Bcl-
2 protein expression [54]. This suggests Bcl-2 regulation through
the hormone receptors, specifically the upregulation of Bcl-2 by
ERa and down-regulation by PR. Here we show that tamoxifen
treatment increases expression of ERa and decreases ERb, which
may lead to the increased expression of Bcl-2.
Highly proliferative neoplastic cells and high histological grade
tumors have been associated with increased expression of cellular
markers for proliferation. Abnormal cyclin D1 expression is
common in female breast cancer [55,56]. Prognostic relevance of
the proliferative proteins cyclinD1 and Ki67 have not been
confirmed in male breast cancer patients. CyclinD1 has been
shown to be overexpressed in 77% of male breast cancer [29].
Interestingly, in a cohort of male breast cancer patients cyclin D1
overexpression was predicative of better patient survival, while
high levels of cyclin A and B expression increase the risk for breast
cancer related death by 2–3 fold [57]. In male PyVT mice,
treatment with tamoxifen increased cyclin D1 expression without
significantly altering tumor growth. This conflicts with the findings
from Nilsson et al. while affirming that cyclin D1 may not be a
suitable molecular marker for male breast cancer.
The differences in the physiology of female and male patients
with breast cancer warrant a different treatment approach,
specifically with regards to hormonal therapy. More research is
needed to determine the role of anti-estrogenic compounds such as
tamoxifen in male breast cancer treatment. Scattered reports are
insufficient to recommend treatment guidelines. Based on the
known differences in the biology of male and female breast cancer,
it is only practical to consider treatment options that do not alter
the hormonal signaling or at least not as a single treatment agent
of breast cancer in men.
This study offers a unique opportunity to study the effects of
certain antineoplastic drugs in a male mammary tumor model.
The results show the effects of treatment with three accepted
antineoplastic drugs that have not been effectively assessed in the
male system due to low clinical occurrence rates of male breast
cancer. The results of this study provide valuable information
toward the better understanding of male breast cancer and may
help guide treatment decisions.
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